Glycosaminoglycans: Use in treatment of diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 11, Issue 2, 2000, Pages 359-368

  Gambaro, Giovanni ^a   Van Der Woude, Fokko J ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEVER; HUMAN; MORPHOMETRICS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0033956620     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. RENINE: De ontwikkeling van het nierfunctie-vervangingsprogramma in Nederland. Statistisch verslag, Erasmus University Rotterdam, The Netherlands, 1998
2. USRDS: Chapter II: Incidence and prevalence of ESRD. Available at: http://www.med.umich.edu/usrds/chapters/ch02/ ch02.html
3. Pastan S, Bailey J: Dialysis therapy. N Engl J Med 338: 1428-1437,1998
4. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
6. Mogensen CE: How to protect the kidney in diabetic patients. Diabetes 46[Suppl 2]: S104-S111, 1997
7. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320: 1161-1165, 1989
8. Pettitt DJ, Nelson RG, Saad MF, Bennett PH, Knowler WC: Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care 16: 310-314, 1993
9. Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH: Is diabetic nephropathy an inherited complication? Kidney Int 41: 719-722, 1991
10. Parving HH, Tarnow L, Rossing P: Genetics of diabetic nephropathy. J Am Soc Nephrol 7: 2509-2517, 1996
11. Parving HH, Osterby R, Anderson PW, Hsueh W: Diabetic nephropathy. In: The Kidney, 5th Ed., edited by Brenner BM, Philadelphia, Saunders, 1996, pp 1864-1892
12. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH: Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. Br Med J 313: 779-784, 1996
13. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: The Steno hypothesis. Diabetologia 32: 219-226, 1989
14. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L: Heparan sulfate proteoglycans of the cardiovascular system: Specific structures emerge but how is synthesis regulated? J Clin Invest 100: S67-S75, 1997
15. Cohen MP, Surma ML: 35S sulfate incorporation into glomerular basement membrane glycosaminoglycans is decreased in experimental diabetes. J Lab Clin Med 98: 715-722, 1981
16. Brown DM, Klein DJ, Michael AF, Oegema TR: 35S-glycosaminoglycan and 35S glycopeptide metabolism by diabetic glomeruli and aorta. Diabetes 31: 418-425, 1995
17. Kanwar YS, Rosenzweig LJ, Linker A, Jakubowski ML: Decreased de novo synthesis of glomerular proteoglycans in diabetes: Biochemical and autoradiographic evidence. Proc Natl Acad Sci USA 80: 2272-2275, 1983
18. Rohrbach DH, Hassel JR, Kleinman HK, Martin GR: Alterations in the basement membrane (heparan sulfate) proteoglycan in diabetic mice. Diabetes 31: 185-188, 1982
19. Rohrbach DH, Wagner CW, Star VL, Martin GR, Brown KS, Yoon JW: Reduced synthesis of basement membrane heparan sulfate proteoglycan in streptozotocin-induced diabetic mice. J Biol Chem 258: 11672-11677, 1983
20. Iozzo RV, Cohen IR, Grässel S, Murdoch AD: The biology of perlecan: The multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302: 625-639, 1994
21. Parthasarathy N, Spiro R: Effect of diabetes on the glycosaminoglycan component of the human glomerular basement membrane. Diabetes 31: 738-741, 1982
22. Shimomura H, Spiro R: Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: Decreased levels of heparan sulfate proteoglycans and laminin. Diabetes 36: 374-381, 1987
23. Wasty F, Alavi MZ, Moore S: Distribution of glycosaminoglycans in the intima of human aortas: Changes in atherosclerosis and diabetes mellitus. Diabetologia 36: 316-322, 1993
24. Vernier RL, Steffes MW, Sissons-Ross S, Mauer M: Heparan sulfate proteoglycan in the glomerular basement membrane in type I diabetes mellitus. Kidney Int 41: 1070-1080, 1992
25. Van den Born J, van den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assman KJM, Weening JJ, Berden JHM: Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 43: 454-463, 1993
26. Van den Born J, Gunnarson K, Bakker MAH, Kjellen L, Kusche-Gullberg M, Maccarana M, Berden JHM, Lindahl U: Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody. J Biol Chem 270: 31303-31309, 1995
27. Tamsma JT, van den Born J, Bruijn JA, Assmann KJM, Weening JJ, Berden JHM, Wieslander J, Schrama E, Hermans J, Veerkamp JH, Lemkes HHPJ, van der Woude FJ: Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 37: 313-320, 1994
28. Van der Pijl JW, Daha MR, Van den Born J, Verhagen NA, Lemkes HH, Bucala R, Berden JH, Zwinderman AH, Bruijn JA, van Es LA, van der Woude FJ: Extracellular matrix in human diabetic nephropathy: Reduced expression of heparan sulphate in skin basement membrane. Diabetologia 41: 791-798, 1998
29. Groffen AJ, Ruegg MA, Dijkman H, van de Velden TJ, Buskens CA, van den Born J, Assmann KJ, Monnens LA, Veerkamp JH, van den Heuvel LP: Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 46: 19-27, 1998
30. Halfter W, Dong S, Schurer B, Cole GJ: Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 273: 25404-25412, 1998
31. Raats CJ, Bakker MA, Hoch W, Tamboer WP, Groffen AJ, van den Heuvel LP, Berden JH, van den Born J: Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 273: 17832-17838, 1998
32. Van der Woude FJ, van Det NF: Heparan sulphate proteoglycans and diabetic nephropathy. Exp Nephrol 5: 180-188, 1997
33. Van Det NF, van den Born J, Tamsma JT, Verhagen NAM, Berden JHM, Bruijn JA, Daha MR, van der Woude FJ: Effects of high glucose on the production of heparan sulfate proteoglycan by human mesangial and glomerular visceral epithelial cells in vitro. Kidney Int 49: 1079-1089, 1996
34. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155, 1984
35. Kagami S, Border WA, Miller DA, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994
36. van Det NF, Tamsma JT, van den Born J, Verhagen NAM, van den Heuvel LPWJ, Lowik CWGM, Berden JHM, Bruijn JA, Daha MR, van der Woude FJ: Differential effects of angiotensin II and transforming growth factor β on the production of heparin sulfate proteoglycan by mesangial cells in vitro. J Am Soc Nephrol 7: 1015-1023, 1996
37. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S, Milanesi C, Pesarini A, Borsatti A, Marchi E, Baggio B: Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 46: 797-806, 1994
38. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Crepaldi G, Marchi E, Venturini AP, Baggio B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 42: 285-291, 1992
39. Ceol M, Nerlich A, Baggio B, Anglani F, Sauer U, Schleicher E, Gambaro G: Increased glomerular α1(IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest 74: 484-495, 1996
40. Oshima Y, Isogai S, Mogama K, Ohuchi H, Ohe K: Protective effect of heparin on renal glomerular anionic sites of streptozotocin-injected rats. Diabetes Res Clin Pract 25: 83-89, 1995
41. Oturai PS, Rasch R, Hasseleger E, Johansen PB, Yokoyama H, Thomsen MK, Myrup B, Kofoed-Enevoldsen A, Deckert T: Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats. Acta Pathol Microbiol Immunol Scand 104: 259-264, 1996
42. Gambaro G, Baggio B: Glycosaminoglycans: A new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant 11: 762-764, 1996
43. Gambaro G, Barbanti M, Marchi E, Baggio B: Therapy with glycosaminoglycans in nephrology. In: Nonanticoagulant Actions of Glycosaminoglycans, edited by Harenberg J, Casu B, New York, Plenum, 1996, pp 281-286
44. Del Prete D, Anglani F, Forino M, Ceol M, Fioretto P, Nosadini R, Baggio B, Gambaro G: Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 40: 1449-1454, 1997
45. Caenazzo C, Garbisa S, Onisto M, Zampieri M, Baggio B, Gambaro G: Effect of glucose and heparin on mesangial α1(IV) COLL and MMP-2/TIMP-2 mRNA expression. Nephrol Dial Transplant 12: 443-448, 1997
46. Caenazzo C, Garbisa S, Ceol M, Baggio B, Borsatti A, Marchi E, Gambaro G: Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: Molecular clues for its activity in nephropathy. Nephrol Dial Transplant 10: 175-184, 1995
47. Marshall SM, Hansen KW, Østerby R, Frystyk J, Ørskov H, Flyvbjerg A: Effects of heparin on renal morphology and albuminuria in experimental diabetes. Am J Physiol 271: E326-E332, 1996
48. Gambaro G, Baggio B: Heparin and diabetic nephropathy [Letter]. Am J Physiol 274: E192, 1998
49. Wright TC, Castellot JJ, Petitou M, Lormeau JC, Choay J, Karnovsky MJ: Structural determinants of heparin's growth inhibitory activity. J Biol Chem 264: 1534-1542, 1989
50. McCaffrey T, Falcone DJ, Brayton CF, Agarwal LA, Well FGP, Weksler BB: Transforming growth factor β activity is potentiated by heparin via dissociation of the transforming growth factor β/alpha2-macroglobulin inactive complex. J Cell Biol 109: 441-448, 1989
51. Hathaway GM, Lubben TH, Traugh JA: Inhibition of casein kinase II by heparin. J Biol Chem 255: 8038-8041, 1980
52. Kolm V, Sauer U, Olgemöller B, Schleicher E: High glucose-induced TGF-β1 regulates mesangial production of heparan sulfate proteoglycan. Am J Physiol 270: F812-F821, 1996
53. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease: The case for transforming growth factor β as a key mediator. Diabetes 44: 1139-1146, 1995
54. Schleicher E, Nerlich A: The role of hyperglycemia in the development of diabetic complications. Horm Metab Res 28: 367-373, 1996
55. Hagège J, Delarue F, Peraldi MN, Sraer JD, Rondeau E: Heparin selectivity inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells. Lab Invest 71: 828-837, 1994
56. Ceol M, Gambaro G, Nerlich A, Baggio B, Anglani F, Forino M, Sauer U, Schleicher ED: Glycosaminoglycan therapy prevents TGF-β1 over-expression and pathological changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000, in press
57. Border WA, Noble NA: Targeting TGF-β for treatment of disease. Nat Med 1: 1000-1001, 1995
58. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995
59. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl acad Sci USA 90: 1814-1818, 1993
60. Myrup B, Hansen PM, Jensen T, Kofoed-Enevoldsen A, Feldt-Rasmussen B, Gram J, Kluft C, Jespersen J, Deckert T: Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345: 421-422, 1995
61. Tamsma JT, van der Woude FJ, Lemkes HHPJ: Effect of sulfated glycosaminoglycans on albuminuria in patients with overt diabetic (type-1) nephropathy. Nephrol Dial Transplant 11: 182-185, 1996
62. Van der Pijl JW, van der Woude FJ, Geelhoed-Duijvestijn PHLM, Fröhlich M, van der Meer FJM, Lemkes HHPJ, van Es LA: Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol 8: 456-462, 1997
63. Solini A, Carraro A, Barzon I, Crepaldi G: Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with microalbuminuria. Diabetes Nutr Metab 7: 304-307, 1994
64. Skrha J, Perusicova J, Pontuch P, Oksa A: Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract 38: 25-31, 1997
65. Poplawska A, Szelachowska M, Topolska J, Wysocka-Solowie B, Kinalska I: Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract 38: 109-114, 1997
66. Dedov I, Shestakova M, Vorontzov A, Palazzini E: A randomized, controlled study of sulodexide therapy for the-treatment of diabetic nephropathy. Nephrol Dial Transplant 12: 2295-2300, 1997
67. Szelanowska M, Poplawska A, Jopdska J, Kinalska I, Grimaldi M: A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin 13: 539-545, 1997
68. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39: 1569-1576, 1995
69. Gambaro G, Venturini AP, Chieco PO, Barbanti M, Marchi E, Borsatti A, Baggio B: Different heparin dosages are needed to ameliorate the evolution of different experimental nephropathies: Does this mean different heparin targets? [Abstract] Kidney Int 47: 689, 1995
70. Nielsen S, Schmitz A, Bacher T, Rehling M, Ingerslev J, Mogensen CE: Transcapillary escape rate and albuminuria in type II diabetes: Effects of short term treatment with low-molecular weight heparin. Diabetologia 42: 60-67, 1999
71. van der Pijl JW, van der Woude FJ, Swart W, van Es LA, Lemkes HHPJ: Effect of danaparoid sodium on hard exudates in diabetic retinopathy. Lancet 350: 1743-1745, 1997
72. Paques M, Massin P, Gaudric A: Growth factors and diabetic retinopathy. Diabet Metabol 23: 125-130, 1997
73. Klein R, Klein BEK: Diabetic eye disease. Lancet 350: 197-204, 1997
74. Larsen AK, Lund DP, Langer R, Folkman J: Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci USA 83: 2964-2968, 1986
75. Jaques LB, Hiebert LM, Wice SM: Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000. J Lab Clin Med 117: 122-130, 1991
76. Hiebert LM, Wice SM, Jaques LB: Antithrombotic activity of oral unfractionated heparin. J Cardiovasc Pharmacol 28: 26-29, 1996
77. Dawes J, Hodson BA, MacGregor IR, Pepper DS, Prowse CV: Pharmacokinetic and biological activities of dermatan sulfate (Mediolanum MF701) in healthy human volunteers. Ann NY Acad Sci 556: 292-303, 1989
78. Solini A, Vergnani L, Ricci F, Crepaldi G: Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 20: 813-817, 1997
79. Velussi M, Cernigoi AM, Dapas F, De Monte A: Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diabetes Nutr Metab 9: 53-58, 1996
80. Obata H, Inoue Y, Kojiro S, Niikura K, Naga T, Kinugasa E, Akizawa T, Ideura T: Influence of heparin administration on bone metabolism in experimental chronic renal failure rats [Abstract]. Nephrol Dial Transplant 11: 46a, 1996
81. Warkentin TE, Levine MN, Hirsh J: Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med 332: 1330-1335, 1995
82. Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172). Thromb Haemostasis 70: 554-561, 1993
83. Hill GR, Hickton C, Henderson S, Patton WN: The use of orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher orgaran concentrations. Clin Lab Haematol 19: 155-157, 1997
84. Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29: 153-163, 1997
85. Kikkawa R, Kitamura E, Fujiwara Y, Arimura T, Haneda M, Shigeta Y: Impaired contractile responsiveness of diabetic glomeruli to angiotensin II: A possible indication of mesangial dysfunction in diabetes mellitus. Biochem Biophys Res Commun 136: 1185-1190, 1986
86. Kanamori A, Abe Y, Matoba K, Yajima Y: Response of cytosolic free calcium to angiotensin II in individual rat mesangial cell cultured in a medium high in glucose. Horm Metab Res 26: 561-562, 1994
87. 2+ independent. Diabetes 44: 759-766, 1995
88. Seal EE, Eaton DC, Gomez LM, Ma H, Ling BN: Extracellular glucose reduces the responsiveness of mesangial cell ion channels to angiotensin II. Am J Physiol 269: F389-F397, 1995
89. Low BC, Ross IK, Grigor MR: Angiotensin II stimulates glucose transport activity in cultured vascular smooth muscle cells. J Biol Chem 267: 20740-20745, 1992
90. Tang W, Richards EM, Raizada MK, Sumners C: Angiotensin II increases glucose uptake and glucose transporter-1 mRNA levels in astroglia. Am J Physiol 268: E384-E390, 1995
91. Tang SS, Diamant D, Rhoads DB, Ingelfinger JR: Angiotensin II (ANG II) regulates glucose uptake in immortalized rat proximal tubular cells (IRPTC) [Abstract]. J Am Soc Nephrol 6: 748, 1995
92. Del Prete D, Anglani F, Ceol M, D'Angelo A, Forino M, Vianello D, Baggio B, Gambaro G: Molecular biology of diabetic glomerulosclerosis. Nephrol Dial Transplant Suppl 8: 20-25, 1998
93. Liu FY, Cogan MG: Role of protein kinase C in proximal bicarbonate absorption and angiotensin signaling. Am J Physiol 258: F927-F933, 1990
94. Wolf G, Neilson EG, Goldfarb S, Ziyadeh FN: The influence of glucose concentration on angiotensin II-induced hypertrophy of proximal tubular cells in culture. Biochem Biophys Res Commun 176: 902-909, 1991
95. Geisterfer AAT, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62: 749-756, 1988
96. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ: Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91: 2268-2274, 1993
97. Wolf G, Mueller E, Stahl RAK, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 92: 1366-1372, 1993
98. Wolf G, Ziyadeh FN, Zahner G, Stahl RAK: Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: Attenuation after stable transfection with c-mas oncogene. Kidney Int 48: 1818-1827, 1995
99. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia: Autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 90: 456-461, 1992
100. Ketteler M, Noble NA, Border WA: Transforming growth factor-β and angiotensin II: The missing link from glomerular hyperfiltration and glomerulosclerosis? Annu Rev Physiol 57: 279-295, 1995
101. van Det NF, Verhagen NAM, Tamsma JT, Berden JHM, Bruijn JA, Daha MR, van der Woude FJ: Regulation of glomerular epithelial cell production of fibronectin and transforming growth factor-β by high glucose, not by angiotensin II. Diabetes 46: 834-840, 1997
102. Border WA: Anticoagulants are of little value in the treatment of renal disease. Am J Kidney Dis 3: 308-312, 1984
103. Gambaro G, Skrha J, Ceriello A: Glycosaminoglycan therapy for long-term diabetic complications? Diabetologia 41: 975-979, 1998